{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:09:02Z","timestamp":1789139342090,"version":"build-2803163510"},"reference-count":97,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Inhibitory antibodies against cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) have antitumor efficacy and are now standard of care in the management of multiple cancer subtypes. However, the use is complicated by the development of autoimmunity, which can occur in multiple organ systems. Thyroiditis is the most common immune-related adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (ICI)-associated thyroiditis affects over 10% of treated patients. PD-1 inhibitors are associated with greater risk of thyroid dysfunction relative to CTLA-4 inhibitors, although the highest risk occurs with combined anti-CTLA-4 and anti-PD-1 treatment. Onset is typically rapid, within weeks to months and both hyperthyroidism and hypothyroidism can occur. The most frequent pattern of thyroid dysfunction is transient hyperthyroidism with evolution to hypothyroidism over four to six weeks. Most cases are asymptomatic and resolve without dedicated treatment. There is no sex or age predominance, and predictive risk factors have not been reliably identified. Thyroid autoantibodies are variably present and are not clearly related to the risk or progression of thyroid dysfunction following treatment with an ICI. Observational data suggest that development of ICI-associated thyroiditis may predict improved survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>ICI-associated thyroiditis is a distinct clinical entity. Mechanisms underlying etiology remain largely unknown. Awareness among health professionals is important to limit morbidity and avoid unnecessary periods of untreated hypothyroidism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2020.0032","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T02:32:49Z","timestamp":1586313169000},"page":"1458-1469","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":75,"title":["Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer"],"prefix":"10.1177","volume":"30","author":[{"given":"Christopher A.","family":"Muir","sequence":"first","affiliation":[{"name":"Nothern Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia."},{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, St. Leonards, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[{"name":"Nothern Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia."},{"name":"Melanoma Medical Oncology, Melanoma Institute Australia, Wollstonecraft, Australia."},{"name":"Department of Medical Oncology and Royal North Shore Hospital, St. Leonards, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[{"name":"Nothern Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia."},{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, St. Leonards, Australia."},{"name":"Department of Endocrinology, Royal North Shore Hospital, St. Leonards, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa H.M.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Nothern Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia."},{"name":"Cancer Genetics Laboratory, Kolling Institute of Medical Research, St. Leonards, Australia."},{"name":"Department of Endocrinology, Royal North Shore Hospital, St. Leonards, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.06.003"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.180870"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021194"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7629"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6601"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2017.11.002"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0418"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13297"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0833"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.03.006"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01058-x"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2017.09.008"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4560"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0562"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0208"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13483"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP171832.OR"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216954"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0810"},{"key":"e_1_3_3_64_2","first-page":"140092","article-title":"A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu C","year":"2015","unstructured":"Yu C, , Chopra IJ, , Ha E. 2015. A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinol Diab Metab Case Rep, 2015:140092.","journal-title":"Endocrinol Diab Metab Case Rep"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-018-1708-x"},{"key":"e_1_3_3_66_2","first-page":"18","article-title":"A case of pembrolizumab-induced severe dka and hypothyroidism in a patient with metastatic melanoma","volume":"2019","author":"Hakami OA","year":"2019","unstructured":"Hakami OA, , Ioana J, , Ahmad S, , Tun TK, , Sreenan S, , McDermott JH. 2019. A case of pembrolizumab-induced severe dka and hypothyroidism in a patient with metastatic melanoma. Endocrinol Diab Metab Case Rep, 2019:18-0153.","journal-title":"Endocrinol Diab Metab Case Rep"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00170"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.244.33"},{"key":"e_1_3_3_69_2","first-page":"345","article-title":"Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma","volume":"32","author":"Ariyasu H","year":"2018","unstructured":"Ariyasu H, , Inaba H, , Ota T, , Yamaoka H, , Furukawa Y, , Iwakura H, , Doi N, , Yamamoto Y, , Akamizu T. 2018. Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. in vivo, 32:345\u2013351.","journal-title":"in vivo"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00423"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0472"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01871-7"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219835912"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0213-x"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2018.05.005"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017348"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0375"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13028"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2134-z"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.038"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01430"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-018-0267-x"},{"key":"e_1_3_3_85_2","first-page":"1035","article-title":"Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer","volume":"31","author":"Maekura T","year":"2017","unstructured":"Maekura T, , Naito M, , Tahara M, , Ikegami N, , Kimura Y, , Sonobe S, , Kobayashi T, , Tsuji T, , Minomo S, , Tamiya A, , Atagi S. 2017. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer. In Vivo, 31:1035\u20131039.","journal-title":"In Vivo"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00432"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0079"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00813"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1159\/000485742"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13520"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_3_3_95_2","first-page":"e1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"19","author":"Kim HI","year":"2017","unstructured":"Kim HI, , Kim M, , Lee SH, , Park SY, , Kim YN, , Kim H, , Jeon MJ, , Kim TY, , Kim SW, , Kim WB, , Kim SW, , Lee DH, , Park K, , Ahn MJ, , Chung JH, , Shong YK, , Kim WG, , Kim TH. 2017. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. OncoImmunology, 19:e1375642.","journal-title":"OncoImmunology"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.08.008"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2805-3"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2020.0032","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2020.0032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2020.0032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:07:12Z","timestamp":1777586832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2020.0032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":97,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1089\/thy.2020.0032"],"URL":"https:\/\/doi.org\/10.1089\/thy.2020.0032","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}